ES2093833T3 - Composicion y metodo que contiene (s)-metoprolol opticamente puro. - Google Patents

Composicion y metodo que contiene (s)-metoprolol opticamente puro.

Info

Publication number
ES2093833T3
ES2093833T3 ES92910858T ES92910858T ES2093833T3 ES 2093833 T3 ES2093833 T3 ES 2093833T3 ES 92910858 T ES92910858 T ES 92910858T ES 92910858 T ES92910858 T ES 92910858T ES 2093833 T3 ES2093833 T3 ES 2093833T3
Authority
ES
Spain
Prior art keywords
optically pure
methoprolol
composition
method containing
metoprolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92910858T
Other languages
English (en)
Inventor
James W Young
Timothy J Barberich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ES2093833T3 publication Critical patent/ES2093833T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/40—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups and esterified hydroxy groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04—Saturated ethers
    • C07C43/10—Saturated ethers of polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/164—Unsaturated ethers containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

METOPROLOL (S) OPTICAMENTE PURO, QUE NO CONTIENE SUSTANCIALMENTE EL ENANTIOMERO (R) Y ES UN POTENTE BLOQUEADOR BETA PARA EL TRATAMIENTO DEL INFARTO DE MIOCARDIO Y PARA EL ALIVIO DE LOS SINTOMAS DE LA ANGINA DE PECHO, AL ARRITMIA CARDIACA Y LA HIPERTENSION DE INDIVIDUOS. SE PRESENTA UN METODO EN EL QUE SE UTILIZA EL ENANTIOMERO DE METAPROLOL CONFIGURACIONAL (S) OPTICAMENTE PURO PARA EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES AL TIEMPO QUE SE REDUCEN LOS EFECTOS SECUNDARIOS NO DESEADOS ASOCIADOS A LA ADMINISTRACION DE BLOQUEADORES BETA.
ES92910858T 1991-03-18 1992-03-10 Composicion y metodo que contiene (s)-metoprolol opticamente puro. Expired - Lifetime ES2093833T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67099591A 1991-03-18 1991-03-18

Publications (1)

Publication Number Publication Date
ES2093833T3 true ES2093833T3 (es) 1997-01-01

Family

ID=24692726

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910858T Expired - Lifetime ES2093833T3 (es) 1991-03-18 1992-03-10 Composicion y metodo que contiene (s)-metoprolol opticamente puro.

Country Status (11)

Country Link
US (1) US5362757A (es)
EP (2) EP0677291A3 (es)
JP (1) JPH0825927B2 (es)
AT (1) ATE141049T1 (es)
AU (1) AU660984B2 (es)
CA (1) CA2106494A1 (es)
DE (1) DE69212646T2 (es)
DK (1) DK0576617T3 (es)
ES (1) ES2093833T3 (es)
GR (1) GR3021543T3 (es)
WO (1) WO1992016197A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335213A (en) 1996-11-20 2001-02-23 Astra Ab Metoprolol and a method of preparing metoprolol by reacting p-(2-methoxyethyl)phenol and epichlorohydrin and isopropylamine
KR100332399B1 (ko) * 1999-02-22 2002-04-13 김경호 메토프롤롤 라세미체로부터 메토프롤롤 에난티오머의 제조방법
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
MXPA06009054A (es) * 2004-02-11 2007-04-16 Athpharma Ltd Composiciones cronoterapeuticas y metodos de su uso.
JP2006182740A (ja) * 2004-12-28 2006-07-13 Daiso Co Ltd グリシジルスルホナート誘導体の製造法
JP5240586B2 (ja) 2007-01-29 2013-07-17 ブイライフ サイエンス テクノロジーズ ピーブイティー リミテッド 糖尿病性合併症治療用薬学的組成物
CN101254182B (zh) * 2008-03-10 2010-09-08 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物
CN101732248B (zh) * 2010-01-20 2011-08-17 白求恩医科大学制药厂 一种酒石酸美托洛尔注射液及其制备方法
SI2814473T1 (sl) * 2012-02-16 2019-03-29 Saniona A/S Farmacevtske sestave za kombinirano terapijo
KR101379383B1 (ko) * 2012-03-23 2014-04-02 주식회사 알에스텍 고순도 ⒮―메토프롤롤의 제조방법
CN107666913B (zh) 2015-03-03 2021-11-26 萨尼奥纳有限责任公司 特索芬辛，β-受体阻滞剂组合制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404073D0 (sv) * 1984-08-13 1984-08-13 Haessle Ab Method for the synthesis of pharmacologically acitve compounds and intermediates for such synthesis
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
DE3725273A1 (de) * 1987-07-30 1989-02-09 Basf Ag Verfahren zur synthese von enantiomeren des propafenons sowie diese enthaltende therapeutische mittel
US4818541A (en) * 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
SE8801518D0 (sv) * 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
JPH037217A (ja) * 1989-03-28 1991-01-14 Nitto Denko Corp メトプロロール含有テープ製剤
JPH0311014A (ja) * 1989-06-08 1991-01-18 Nisshin Oil Mills Ltd:The 外用ゲル製剤

Also Published As

Publication number Publication date
JPH06505994A (ja) 1994-07-07
EP0677291A3 (en) 1996-08-07
DE69212646D1 (de) 1996-09-12
DE69212646T2 (de) 1997-03-13
AU660984B2 (en) 1995-07-13
CA2106494A1 (en) 1992-09-19
DK0576617T3 (da) 1996-12-30
ATE141049T1 (de) 1996-08-15
JPH0825927B2 (ja) 1996-03-13
EP0576617A1 (en) 1994-01-05
WO1992016197A1 (en) 1992-10-01
GR3021543T3 (en) 1997-02-28
EP0677291A2 (en) 1995-10-18
AU1774192A (en) 1992-10-21
EP0576617B1 (en) 1996-08-07
US5362757A (en) 1994-11-08

Similar Documents

Publication Publication Date Title
ES2093833T3 (es) Composicion y metodo que contiene (s)-metoprolol opticamente puro.
CA2073181A1 (en) Optically pure r(-) albuterol for treating asthma
CA2015429A1 (en) High strength alpha-beta titanium-base alloy
DK0611831T3 (da) Titanlegering til fremstilling af plader
LU90999I2 (fr) Escitalopram et ses sels pharmaceutiquement acceptables (cipralex)
MX167586B (es) Membrana compuesta
DE3887273D1 (de) 2',3'-Dideoxy-2'-fluornucleoside.
AU4876993A (en) Anti-arrhythmic, analgesically acting phthalazinone derivatives that break through multi-drug resistance
LU88822I2 (fr) Stavudine et ses dérivés pharmaceutiquement acceptables (Zerit R)
AU5107085A (en) 1,4-dihydropyridine carboxamide derivatives
USD309107S (en) Blank for package or the like
NO913188D0 (no) Fremgangsmaate ved fremstilling av enantiomert rene polysubstituerte 1,4-dihydropyridiner.
TW326396B (en) Metal surgical cable
DE59006668D1 (de) Trinkgefäss oder dgl.
USD308341S (en) Blank for package or the like
ES8800904A1 (es) Procedimiento para preparar derivados de 1,4-dihidropiridina con actividad cardiovascular
NO890681D0 (no) Fremgangsmaate for fremstilling av alkanoyl- og aroyloxazoloner.
ES296588Y (es) Sombrerete conico a base de lamina metalica para producir el armazon de corona de una corona de revestimiento metaloceramica.
EP0351017A3 (en) Pharmaceutical composition useful for the treatment of cardiovascular diseases
USD276557S (en) Combined head light fairing and instrument panel for motorcycles
DE3779314D1 (de) Niob, vanadium und molybdaen enthaltende titan-aluminiumlegierungen.
DE69119900D1 (de) Verwendung von Prostaglandin F3alpha als okulares Hypotensivum
ES2106922T3 (es) 3-beta-derivados de digitoxigenina y dihidrodigitoxigenina y composiciones farmaceuticas que los contienen para el tratamiento de la hipertension.
USD304953S (en) Guitar headstock
JPH01133105U (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 576617

Country of ref document: ES